Quantification of the GH/IGF-axis components: Lessons from human studies

Domestic Animal Endocrinology

Volumn 43, Issue 2, 2012, Pages 186-197

  Frystyk, J ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Bioactive IGF I; Free GH; Free IGF I; GH; KIRA assay; Ultrafiltration

Indexed keywords

CARRIER PROTEIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOTROPIN BINDING PROTEIN; SOMATOTROPIN-BINDING PROTEIN;

BIOASSAY; BLOOD; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOASSAY; ISOLATION AND PURIFICATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; REVIEW; ULTRAFILTRATION;

BIOLOGICAL ASSAY; CARRIER PROTEINS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RECEPTORS, SOMATOTROPIN; TRANSFECTION; ULTRAFILTRATION;

EID: 84863777017     PISSN: 07397240     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.domaniend.2011.11.005     Document Type: Review

References (78)

1. Rinderknecht E., Humbel R.E. Primary structure of human insulin-like growth factor II. FEBS Lett 1978, 89:283-286.
2. Rinderknecht E., Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978, 253:2769-2776.
3. Rechler M.M. Insulin-like growth factor binding proteins. Vitam Horm 1993, 47:1-114.
4. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
5. Rajaram S., Baylink D.J., Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997, 18:801-831.
6. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004, 14:337-375.
7. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Re 2002, 23:824-854.
8. Guler H.P., Zapf J., Schmid C., Froesch E.R. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989, 121:753-758.
9. Zapf J., Hauri C., Futo E., Hussain M., Rutishauser J., Maack C.A., Froesch E.R. Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J Clin Invest 1995, 95:179-186.
10. Adams T.E., Epa V.C., Garrett T.P., Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000, 57:1050-1093.
11. De Meyts P., Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002, 1:769-783.
12. LeRoith D., Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007, 3:302-310.
13. Clemmons D.R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007, 6:821-833.
14. Van den Brande J.L. A personal view on the early history of the insulin-like growth factors. Horm Res 1999, 51(suppl 3):149-175.
15. Frystyk J., Freda P., Clemmons D.R. The current status of IGF-I assays--a 2009 update. Growth Horm IGF Res 2010, 20:8-18.
16. Sadick M.D. Kinase Receptor Activation (Kira): a rapid and accurate alternative to endpoint bioassays. Dev Biol Stand 1999, 97:121-133.
17. Furlanetto R.W., Underwood L.E., Van Wyk J.J., D'Ercole A.J. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977, 60:648-657.
18. Zapf J., Walter H., Froesch E.R. Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest 1981, 68:1321-1330.
19. Clemmons D.R. IGF-I assays: current assay methodologies and their limitations. Pituitary 2007, 10:121-128.
20. Daughaday W.H., Parker K.A., Borowsky S., Trivedi B., Kapadia M. Measurement of somatomedin-related peptides in fetal, neonatal, and maternal rat serum by insulin-like growth factor (IGF) I radioimmunoassay, IGF-II radioreceptor assay (RRA), and multiplication-stimulating activity RRA after acid-ethanol extraction. Endocrinology 1982, 110:575-581.
21. Clemmons D.R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011, 57:555-559.
22. Burns C., Rigsby P., Moore M., Rafferty B. The First International Standard for Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 2009, 19:457-462.
23. Chen J.W., Højlund K., Beck-Nielsen H., Sandahl Christiansen J., Orskov H., Frystyk J. Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J Clin Endocrinol Metab 2005, 90:366-371.
24. Frystyk J., Højlund K., Rasmussen K.N., Jørgensen S.P., Wildner-Christensen M., Ørskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J Clin Endocrinol Metab 2002, 87:260-266.
25. Frystyk J., Ivarsen P., Skjaerbaek C., Flyvbjerg A., Pedersen E.B., Orskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999, 56:2076-2084.
26. Jones J.I., D'Ercole A.J., Camacho-Hubner C., Clemmons D.R. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci U S A 1991, 88:7481-7485.
27. Skjaerbaek C., Frystyk J., Orskov H., Kissmeyer-Nielsen P., Jensen M.B., Laurberg S., Møller N., Flyvbjerg A. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 1998, 83:2445-2449.
28. Blat C., Villaudy J., Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 1994, 93:286-290.
29. Rehage M., Mohan S., Wergedal J.E., Bonafede B., Tran K., Hou D., Phang D., Kumar A., Qin X. Transgenic overexpression of pregnancy-associated plasma protein-A increases the somatic growth and skeletal muscle mass in mice. Endocrinology 2007, 148:6176-6185.
30. Chen J.W., Ledet T., Orskov H., Jessen N., Lund S., Whittaker J., De Meyts P., et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 2003, 284:E1149-E1155.
31. Denley A., Bonython E.R., Booker G.W., Cosgrove L.J., Forbes B.E., Ward C.W., Wallace J.C. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 2004, 18:2502-2512.
32. Frystyk J., Skjaerbaek C., Dinesen B., Orskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 1994, 348:185-191.
33. Nindl B.C., Alemany J.A., Tuckow A.P., Rarick K.R., Staab J.S., Kraemer W.J., Maresh C.M., et al. Circulating bioactive and immunoreactive IGF-I remain stable in women, despite physical fitness improvements after 8 weeks of resistance, aerobic, and combined exercise training. J Appl Physiol 2010, 109:112-120.
34. Chen J.W., Nielsen M.F., Caumo A., Vilstrup H., Christiansen J.S., Frystyk J. Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol 2006, 155:285-292.
35. Brugts M.P., Ranke M.B., Hofland L.J., van der Wansem K., Weber K., Frystyk J., Lamberts S.W., et al. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J Clin Endocrinol Metab 2008, 93:2539-2545.
36. Brugts M.P., van den Beld A.W., Hofland L.J., van der Wansem K., van Koetsveld P.M., Frystyk J., Lamberts S.W., et al. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab 2008, 93:2515-2522.
37. Ivarsen P., Chen J.W., Tietze I., Christiansen J.S., Flyvbjerg A., Frystyk J. Marked reductions in bioactive insulin-like growth factor I (IGF-I) during hemodialysis. Growth Horm IGF Res 2010, 20:156-161.
38. Arafat A.M., Weickert M.O., Frystyk J., Spranger J., Schöfl C., Möhlig M., Pfeiffer A.F. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 2009, 94:5093-5103.
39. Brismar K., Fernqvist-Forbes E., Wahren J., Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994, 79:872-878.
40. Frystyk J. Aging somatotropic axis: mechanisms and implications of insulin-like growth factor-related binding protein adaptation. Endocrinol Metab Clin North Am 2005, 34:865-876. viii.
41. Conover C.A., Lee P.D., Kanaley J.A., Clarkson J.T., Jensen M.D. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992, 74:1355-1360.
42. Frystyk J., Grøfte T., Skjaerbaek C., Orskov H. The effect of oral glucose on serum free insulin-like growth factor-I and -II in healthy adults. J Clin Endocrinol Metab 1997, 82:3124-3127.
43. Yan X., Baxter R.C., Firth S.M. Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab 2010, 95:1412-1420.
44. Skjaerbaek C., Frystyk J., Orskov H., Flyvbjerg A. Free IGF-I, IGFBP-1, and the binary complex of IGFBP-1 and IGF-I are increased during human pregnancy. Horm Res 2004, 62:215-220. Free IGF-I.
45. Møller A.V., Jørgensen S.P., Chen J.W., Larnkjaer A., Ledet T., Flyvbjerg A., Frystyk J. Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro. Eur J Endocrinol 2006, 155:297-305.
46. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003, 13:113-170.
47. Giustina A., Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998, 19:717-797.
48. Frystyk J. Utility of free IGF-I measurements. Pituitary 2007, 10:181-187.
49. Varewijck A.J., Lamberts S.W., Uitterlinden P., Hofland L.J., Janssen J.A. IGF-I bioactivity better reflects growth hormone deficiency than total IGF-I. J Clin Endocrinol Metab 2011, 96:2248-2254.
50. Jørgensen J.O., Feldt-Rasmussen U., Frystyk J., Chen J.W., Kristensen L.Ø., Hagen C., Ørskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005, 90:5627-5631.
51. Rubeck K.Z., Madsen M., Andreasen C.M., Fisker S., Frystyk J., Jørgensen J.O. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol 2010, 163:717-726.
52. Chapman I.M., Hartman M.L., Pieper K.S., Skiles E.H., Pezzoli S.S., Hintz R.L., Thorner M.O. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 1998, 83:2836-2842.
53. Rasmussen M.H. Obesity, growth hormone and weight loss. Mol Cell Endocrinol 2010, 316:147-153.
54. Rasmussen M.H., Hvidberg A., Juul A., Main K.M., Gotfredsen A., Skakkebæk N.E., Hilsted J. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995, 80:1407-1415.
55. Scacchi M., Pincelli A.I., Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999, 23:260-271.
56. Frystyk J., Vestbo E., Skjaerbaek C., Mogensen C.E., Orskov H. Free insulin-like growth factors in human obesity. Metabolism 1995, 44(suppl 4):37-44.
57. Frystyk J., Brick D.J., Gerweck A.V., Utz A.L., Miller K.K. Bioactive insulin-like growth factor-I in obesity. J Clin Endocrinol Metab 2009, 94:3093-3097.
58. Frystyk J., Ritzel R.A., Maubach J., Büsing M., Lück R., Klempnauer J., Schmiegel W., Nauck M.A. Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis. J Clin Endocrinol Metab 2008, 93:1758-1766.
59. Hedman C.A., Frystyk J., Lindström T., Chen J.W., Flyvbjerg A., Ørskov H., Arnqvist H.J. Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. J Clin Endocrinol Metab 2004, 89:6305-6309.
60. Gleeson H.K., Lissett C.A., Shalet S.M. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab 2005, 90:1061-1067.
61. Fisker S. Physiology and pathophysiology of growth hormone-binding protein: Methodological and clinical aspects. Growth Horm IGF Res 2006, 16:1-28.
62. Leung K.C., Doyle N., Ballesteros M., Waters M.J., Ho K.K. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000, 85:4712-4720.
63. Brugts M.P., van Duijn C.M., Hofland L.J., Witteman J.C., Lamberts S.W., Janssen J.A. IGF-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes 2010, 59:505-508.
64. Heald A.H., Kaushal K., Siddals K.W., Rudenski A.S., Anderson S.G., Gibson J.M. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006, 114:371-376.
65. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96:7324-7329.
66. Domené H.M., Bengolea S.V., Martínez A.S., Ropelato M.G., Pennisi P., Scaglia P., Heinrich J.J., Jasper H.G. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004, 350:570-577.
67. Domené H.M., Martínez A.S., Frystyk J., Bengolea S.V., Ropelato M.G., Scaglia P.A., Chen J.W., Heuck C., Wolthers O.D., Heinrich J.J., Jasper H.G. Normal growth spurt and final height despite low levels of all forms of circulating insulin-like growth factor-I in a patient with acid-labile subunit deficiency. Horm Res 2007, 67:243-249.
68. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96:7324-7329.
69. Yakar S., Rosen C.J., Beamer W.G., Ackert-Bicknell C.L., Wu Y., Liu J.L., Ooi G.T., Setser J., Frystyk J., Boisclair Y.R., LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002, 110:771-781.
70. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Med Sci Sports Exerc 2010, 42:58-66.
71. Binoux M., Hossenlopp P. Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab 1988, 67:509-514.
72. Lalou C., Binoux M. Evidence that limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3) occurs in the normal state outside of the bloodstream. Regul Pept 1993, 48:179-188.
73. Jeyaratnaganthan N., Grønbaek H., Holland-Fischer P., Espelund U., Chen J.W., Flyvbjerg A., Vilstrup H., Frystyk J. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum. Clin Endocrinol (Oxf) 2010, 72:625-632.
74. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991, 12:424-449.
75. Frystyk J., Andreasen C.M., Fisker S. Determination of free growth hormone. J Clin Endocrinol Metab 2008, 93:3008-3014.
76. Hansen T.K., Fisker S., Hansen B., Sørensen H.H., Christiansen J.S., Jørgensen J.O., Ørskov H. Impact of GHBP interference on estimates of GH and GH pharmacokinetics. Clin Endocrinol 2002, 57:779-786.
77. Wan Y., Zheng Y.Z., Harris J.M., Brown R., Waters M.J. Epitope map for a growth hormone receptor agonist monoclonal antibody, MAb 263. Mol Endocrinol 2003, 17:2240-2250.
78. Fisker S., Frystyk J., Skriver L., Vestbo E., Ho K.K., Orskov H. A simple, rapid immunometric assay for determination of functional and growth hormone-occupied growth hormone-binding protein in human serum. Eur J Clin Invest 1996, 26:779-785.